The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma.
D. D. Eisenstat
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
L. B. Nabors
Consultant or Advisory Role - Boehringer Ingelheim (U)
W. P. Mason
No relevant relationships to disclose
J. R. Perry
No relevant relationships to disclose
W. R. Shapiro
Research Funding - Boehringer Ingelheim
P. Kavan
No relevant relationships to disclose
S. Phuphanich
Research Funding - Boehringer Ingelheim
Y. Fu
Employment or Leadership Position - Boehringer Ingelheim
X. J. Cong
Employment or Leadership Position - Boehringer Ingelheim
M. Shahidi
Employment or Leadership Position - Boehringer Ingelheim (U)
D. A. Reardon
Consultant or Advisory Role - EMD Serono
Honoraria - EMD Serono; Genentech; Merck; Roche; Schering-Plough